Reply to: “Comment on – A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in the Republic of Korea”

First of all, we greatly appreciate the letter from Yu et al.,1 which addressed several concerns regarding our study2 where we concluded that the risk of hepatocellular carcinoma (HCC) was not statistically different between patients treated with entecavir (ETV) vs. tenofovir disoproxil fumarate (TDF) for chronic hepatitis B virus (HBV) infection. Actually, the controversy concerning which antiviral agent is better in improving prognosis among patients with chronic HBV infection remains, however, the level of evidence favoring the use of any specific antiviral agent has been weak.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research